Welcome to CONCI
For over 45 years, CONCI has remained a staple in the Ohio weight loss community. Why? Because our programs work! A group of licensed medical professionals with specialized education in obesity management design every program....
Ongoing Research: Effects of VLCD and Drug Treatment for Obesity. (Protocol I. Protocol F. CONCI)
Five-year Maintenance Results of an Obesity Drug Following a Very Low Calorie Diet (VLCD) Presented at Obesity Week, 2013
J Loper, R Lutes, T Broyles, R May, E Baltes.
Naltrexone SR/Bupropion SR Combination Therapy Reduces Total and Visceral Adiposity in Overweight and Obese Subjects in the COR-1 Study. American Diabetes Association, 2011.
Smith S, T Church, J Goohas, C Griffin, W Harper, D Krieger, J Loper, Smudahar, C Woodrugg, M Guittalauria, E Henry, D Kim, E Dunayevich.
Naltrexone SR/Bupropion SR Therapy Reduced Body Weight and HgbA1C in Overweight/Obese Women with Type 2 Diabetes. American Diabetes Association, 2011.
P Hollander, J Loper, L Mignon, C Burns, R Harris-Collzao, D Kim.
Drug Treatment following a VLCD (Very Low Energy Diet). Obesity, Research Journal, 2010
Loper J, RA Lutes, JT Broyles, EJ Baltes, RK May.
Completed Research: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release, SR/Buproprion and Placebo in Obese Subjects. 2007-2009.
Clinical Experience in a Comprehensive Weight-Management Center in the Management of Eating Disorders and Obesity, Humana Press, 2005
J Loper, RA Lutes, Edited by DJ Goldstein.
Very Low Calorie Diets in the 21st Century, ADA Weight Management Newsletter, 2004.
J Loper.